共 50 条
- [21] Patient-reported outcomes in high-risk HR+ /HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB studyEUROPEAN JOURNAL OF CANCER, 2024, 196Garcia-Saenz, Jose AngelMarme, FrederikUntch, MichaelBonnefoi, HerveKim, Sung-BaeBear, HarryMc Carthy, NicoleGelmon, KarenMartin, MiguelKelly, Catherine M.Reimer, ToralfToi, MasakazuLaw, ErnestBhattacharyya, HelenGnant, MichaelMakris, AndreasSeiler, SabineBurchardi, NicoleNekljudova, ValentinaLoibl, SibylleRugo, Hope S.
- [22] Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trialNature Communications, 15Liang HuangDa PangHongjian YangWei LiShusen WangShude CuiNing LiaoYongsheng WangChuan WangYuan-Ching ChangHwei-Chung WangSeok Yun KangJae Hong SeoKunwei ShenSuphawat LaohawiriyakamolZefei JiangHaiyan WangFrançois LamourGrace SongMichelle CurranChunzhe DuanSanne Lysbet de HaasEleonora RestucciaZhimin Shao
- [23] Quality of life from the Penelope-B study on high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclibANNALS OF ONCOLOGY, 2021, 32 : S410 - S411Garcia-Saenz, J. A.Marme, F.Rugo, S.Untch, M.Bonnefoi, H.Kim, S-B.Bear, H. D.McCarthy, N.Gelmon, K.Martin, M.Kelly, C. M.Reimer, T.Toi, M.Law, E. H.Gnant, M.Makris, A.Seiler, S.Burchardi, N.Nekljudova, V.Loibl, S.
- [24] Ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2-early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trialCANCER RESEARCH, 2024, 84 (09)Hortobagyi, GabrielStroyakovsky, DaniilYardley, DeniseHuang, Chiun-ShenFasching, Peter A.Crown, JohnBardia, AdityaChia, StephenIm, Seock-AhMartin, MiguelLoi, ShereneXu, BingheHurvitz, SaraBarrios, CarlosUntch, MichaelMoroose, RebeccaVisco, FrancesParnizari, FedericoGhaznawi, FarhatLi, ZhengWaters, SorchaChakravartty, ArunavaSlamon, Dennis
- [25] Evaluation of recurrence rate in Canadian patients with stage II/III HR+/HER2-early breast cancer in the real-world settingJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Marques, MaudGambaro, KarenBasik, MarkSaad, FredHassan, Saima NoorBoudreau, DominiqueVincent, FrancoisSt-Hilaire, EveMackay, HelenAbdelsalam, MahmoudGuillemette, StephanieLeite, RicardoCaron, Marc-AndrePatel, ChandniBatist, Gerald
- [26] Patient-reported outcomes among patients with HR+/HER2-early breast cancer: A systematic literature reviewANNALS OF ONCOLOGY, 2020, 31 : S45 - S46Salvo, E. M.Cueto, J.Law, E. H.Da Silva, C. AnicetoCameron, C.Samjoo, I. A.
- [27] Patient & oncologist preferences for adjuvant CDK4/6i therapy in HR+/HER2-early breast cancerANNALS OF ONCOLOGY, 2020, 31 : S321 - S322Beusterien, K.Law, E. H.Hallissey, B.Smith, M. L.Gaschler, M.Maculaitis, M. C.
- [28] Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2-Early Breast CancerFRONTIERS IN ONCOLOGY, 2021, 11Kwon, Mi JeongRyu, Jai MinCho, Soo YounNam, Seok JinKim, Seok WonLee, JeeyeonLee, Soo JungPark, Ji-YoungPark, Ho YongHong, SungjunKim, KyungaHan, JinilMoon, YounghoShin, Young KeeLee, Jeong Eon
- [29] The prediction of Oncotype DX risk group using clinicopathologic factors in patients with HR+/HER2-early breast cancerBREAST, 2023, 68 : S74 - S75Song, R.Lee, D. -E.Lee, S.Kang, H. -S.Han, J. H.Lee, K. S.Sim, S. H.Chae, H.Kwon, Y.Woo, J.Lee, M.Lee, E. -G.Jung, S. -Y.
- [30] A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2-early breast cancerSCIENTIFIC REPORTS, 2017, 7Gong, GyungyubKwon, Mi JeongHan, JinilLee, Hee JinLee, Se KyungLee, Jeong EonLee, Seon-HeuiPark, SarahChoi, Jong-SunCho, Soo YounAhn, Sei HyunLee, Jong WonCho, Sang RaeMoon, YounghoNam, Byung-HoNam, Seok JinChoi, Yoon-LaShin, Young Kee